{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:21:34Z","timestamp":1776964894678,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","award":["CHDS"],"award-info":[{"award-number":["CHDS"]}],"id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41409-023-02102-4","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T13:01:54Z","timestamp":1694005314000},"page":"1400-1402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States"],"prefix":"10.1038","volume":"58","author":[{"given":"Mingqian","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Estrada-Merly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-5339","authenticated-orcid":false,"given":"Anthony E.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana E.","family":"Pezzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-6499","authenticated-orcid":false,"given":"William R.","family":"Drobyski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-5643","authenticated-orcid":false,"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2102_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet."},{"key":"2102_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr. Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2102_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jtct.2022.06.004","volume":"28","author":"B Blue","year":"2022","unstructured":"Blue B. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transpl Cell Ther. 2022;28:345\u20136.","journal-title":"Transpl Cell Ther"},{"key":"2102_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","volume":"28","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transpl Cell Ther. 2022;28:358\u201364.","journal-title":"Transpl Cell Ther"},{"key":"2102_CR5","doi-asserted-by":"publisher","first-page":"e2228877","DOI":"10.1001\/jamanetworkopen.2022.28877","volume":"5","author":"R Alqazaqi","year":"2022","unstructured":"Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J Jr. Zhan F, et al. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw Open. 2022;5:e2228877.","journal-title":"JAMA Netw Open"},{"key":"2102_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10:19.","journal-title":"Blood Cancer J"},{"key":"2102_CR7","doi-asserted-by":"publisher","first-page":"699049","DOI":"10.3389\/fpubh.2021.699049","volume":"9","author":"BM Beech","year":"2021","unstructured":"Beech BM, Ford C, Thorpe RJ Jr. Bruce MA, Norris KC. Poverty, racism, and the public health crisis in America. Front Public Health. 2021;9:699049.","journal-title":"Front Public Health"},{"key":"2102_CR8","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1002\/cncr.33831","volume":"127","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, et al. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021;127:4233\u20139.","journal-title":"Cancer."},{"key":"2102_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","volume":"21","author":"LJ Costa","year":"2015","unstructured":"Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2015;21:701\u20136.","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"key":"2102_CR10","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/cncr.30747","volume":"123","author":"JR Schriber","year":"2017","unstructured":"Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123:3141\u20139.","journal-title":"Cancer."},{"key":"2102_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","volume":"24","author":"G Shouse","year":"2022","unstructured":"Shouse G, Danilov AV, Artz A. CAR T-cell therapy in the older person: indications and risks. Curr Oncol Rep. 2022;24:1189\u201399.","journal-title":"Curr Oncol Rep"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02102-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T14:03:44Z","timestamp":1701439424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02102-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2102"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-02102-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ML, NE, ME, LEP, ANW, JP, WD report no conflicts of interest relevant to this work. AEZ reports research support from PhenomeX not related to the data presented in the current study. CS reports Consulting\/Advisory Board activity with Janssen and Pfizer. LA reports Consulting\/Advisory Board activity with: Janssen, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena; AD reports institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, Sanofi, Sorrento, TeneoBio, consulting\/advisory board activity with BMS, Janssen, Pfizer, Prothena.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}